Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?
Sanaz N. Ghafouri, John M. Timmerman, Sarah M. Larson, Monica Mead
Topics & Concepts
MedicineRefractory (planetary science)LymphomaOncologyInternal medicinePhysicsAstrobiologyCAR-T cell therapy researchCNS Lymphoma Diagnosis and TreatmentIntegrated Circuits and Semiconductor Failure Analysis